Opioid maker Insys to be delisted from NASDAQ following bankruptcy filing—the latest blow to a company that was the best performing initial public offering of 2013.
Shares from opioid maker Insys Therapeutics Inc. will be delisted from the Nasdaq on June 19, the company said in a government filing on Tuesday.
The news follows the company's Chapter 11 bankruptcy filing on Monday, which was filed one week after it agreed to pay $225 million to settle the federal government's criminal and civil investigations into the company's illegal marketing scheme of its highly addictive under-the-tongue fentanyl spray, Subsys.As a result of Monday's bankruptcy filing,"Nasdaq has determined that the Company’s securities will be delisted from Nasdaq.
"The Company does not intend to appeal the determination and, therefore, it is expected that the Company’s securities will be delisted," Insys officials wrote."The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks."In 2012, the Food and Drug Administration approved Subsys to treat cancer patients.
In May, a Boston jury found Kapoor and four other former executives guilty of engaging in a racketeering conspiracy to get doctors to oversubscribe Subsys. The convicted former Insys execs each face up to 20 years in jail. Kapoor is the first head of a drug company to face prison time for his role in the nationwide opioid crisis, which kills 130 Americans a day, according to the Centers for Disease Control and Prevention.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Opioid drugmaker Insys Therapeutics files for bankruptcyDrugmaker Insys Therapeutics Inc filed for Chapter 11 bankruptcy protection on M...
Read more »
How Opioid Drugmaker Insys Could Avoid Paying $225 Million Settlement To U.S.Insys Therapeutics agreed to the settlement last week, but their bankruptcy filing may allow the company to skirt repayment.
Read more »
Insys files for bankruptcy, stock plunges toward record lowShares of Insys Therapeutics Inc. plunged 68% toward a record low in premarket trade Monday, after the specialty pharmaceutical company said it filed for...
Read more »